74 / 76
HIPERTENSIÓN / 2017 / VOL. 22
74
Referencias
1. Ellershaw DC, Gurney AM. Mechanisms of hydralazine induced vasodilation in rabbit aorta and pulmonary artery. The results suggest that the main
action of hydralazine is to inhibit the IP(3)-induced release of Ca(2+) from the sarcoplasmic reticulum in vascular smooth muscle cells. Br J Pharmacol.
2001;134:621-631.
2. Kaplan NM. Treatment of hypertension: Drug therapy. Chapter 7. En Kaplan NM. Clinical Hypertension. Fifth Edition. Baltimore, Williams and Wilkins.
P. 182-267.
3. Yancy CW, Jessup M, Bozkurt B et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the management of heart failure.
Circulation. 2017;136:e137-e161.
4. Cohn JN, Archibald DG, Ziesche S et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration
Cooperative Study. N Engl J Med. 1986;314:1547-1552.
5. Taylor AL, Ziesche S, Yancy C et al. for African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks
with heart failure. N Engl J Med. 2004;351:2049-2057
6. Daiber A1, Mülsch A, Hink U et al.The oxidative stress concept of nitrate tolerance and the antioxidant properties of hydralazine. Am J Cardiol.
2005;96(7B):25i-36i.
7. Cohn JN, Johnson G, Ziesche N et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.
N Engl J Med. 1991;325:303-311.
8. Cameron HA, Ramsay LE. The lupus syndrome induced by hydralazine: a common complication with low dose treatment. Br Med J 1984;289:410–412.
9. Handler J. Hydralazine-induced lupus erythematosis. J Clin Hypertens. 2012;14:133-136.
10. Van Zwieten PM, Thoolen MJMC, Timmermans PBWM. The pharmacology of centrally acting antihypertensive drugs. Br J Clin. Pharmac. 1983;15:455S-462S
11. Prichard BNC, Boaks AJ. Labetalol in long term treatment of hypertension. Br J Clin Pharmacol 1976;3 (Suppl):743.
12. Palatini P, Agabiti Rosei Casiglia. Identification and management of the hypertensive patients with elevated heart rate; statement of the Second Consensus
Conference endorsed by European Society of Hypertension Consensus Meeting. J Hypertens 2016;34:813-821.
13. Robertson JIS. Labetalol: the nineteen-eighties. Br J Clin Pharmacol. 1982;13 (1 Suppl):137S-141S.
14. Hoefnagel CA, Schornagel J, Valdés Olmos RA. [131I]metaiodobenzylguanidine therapy of malignant pheochromocytoma: interference of medication.
J Nucl Biol Med. 1991;35:308-312.
15. Report of the National High Blood Pressure Education ProgramWorking Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol. 2000;183:S1-S22.
16. Visintin C, Mugglestone MA, Almerie MQ et al; Guideline Development Group. Management of hypertensive disorders during pregnancy: summary of
NICE guidance. BMJ. 2010;341:c2207
17. The Task Force on Hypertension in Pregnancy. Report of the American College of Obstetricians and Gynecologists´ Obstetrics and Gynecology
2013:122:1123-1131.
18. Magee LA, Pels A, Helewa M ert al. Canadian Hypertensive Disorders of Pregnancy Working Group. Diagnosis, evaluation, and management of the
hypertensive disorders of pregnancy: executive summary. J Obstet Gynaecol Can. 2014;36:416-441.
19. Roberts JM. Pathophysiology of ischemic placental disease. Semin Perinatol. 2014;38:139–145.
20. Ounsted MK, Moar VA, Good FJ, Redman CW. Hypertension during pregnancy with and without specific treatment; the development of the children
at the age of four years. BJOG. 1980;87:19-24.
21. Pasker-de Jong P, Zielhuis G, van Gelder M et al. Antihypertensive treatment during pregnancy and functional development at primary school age in
a historical cohort study. BJOG 2010;117:1080–1087.
22. Firoz T, Magee LA, MacDonell K et al. for the Community Level Interventions for Preeclampsia (CLIP) working Group. Oral antihypertensive therapy for
severe hypertension in pregnancy; a systematic review. BJOG 2014;121:1210-1230.
23. Committee on Obstetric Practice. Committee Opinion No. 692: Emergent therapy for acute-onset, severe hypertension during pregnancy and the
postpartum period. Obstet Gynecol. 2017;129:e90-e95.
24. Heida KY, Zeeman GG, Van Veen TR, Hulzebos CV. Neonatal side effects of maternal labetalol treatment in severe preeclampsia. Early Hum Dev.
2012;88:503-507.
25. Magee LM, von Dadelszen P, Rey E et al. Less-tight versus tight control of hypertension in pregnancy. N Eng J M 2015;372:407-417.
26. Task Force on Hypertension in Pregnancy of the American College of Obstetricians and Gynecologists. Hypertension in pregnancy. Report of the
American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy.
Obstet Gynecol. 2013;122:1122-1131.